VistaGen Therapeutics, Inc.
VTGN · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $77 | $105 | $25 | $245 |
| - Cash | $67 | $119 | $17 | $68 |
| + Debt | $2 | $2 | $2,130 | $3 |
| Enterprise Value | $11 | -$13 | $2,138 | $180 |
| Revenue | $0 | $1 | -$0 | $1 |
| % Growth | -54.3% | 568.7% | -120.5% | – |
| Gross Profit | $0 | $1 | -$0 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$55 | -$32 | -$59 | -$47 |
| % Margin | -11,386.4% | -3,050.1% | 25,874.9% | -4,242.8% |
| Net Income | -$51 | -$29 | -$59 | -$48 |
| % Margin | -10,579.8% | -2,759.6% | 26,100.4% | -4,307.2% |
| EPS Diluted | -1.67 | -1.52 | -8.51 | -7.38 |
| % Growth | -9.9% | 82.1% | -15.3% | – |
| Operating Cash Flow | -$42 | -$26 | -$50 | -$45 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$42 | -$26 | -$50 | -$45 |